UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 565

Sortiert nach

Safety, efficacy and renal effect of febuxostat in patients with moderate-to-severe kidney dysfunction

Hypertension research, 2014-10, Vol.37 (10), p.919-925

2014

Volltextzugriff (PDF)

Decreased extra-renal urate excretion is a common cause of hyperuricemia

Nature communications, 2012-04, Vol.3 (1), p.764-764, Article 764

2012

Volltextzugriff (PDF)

Comparative study of a novel selective urate reabsorption inhibitor “dotinurad” among patient groups with different stages of renal dysfunction

Clinical and experimental nephrology, 2021-12, Vol.25 (12), p.1336-1345

2021

Volltextzugriff (PDF)

Uric acid-lowering effect of dotinurad, a novel selective urate reabsorption inhibitor, in hypertensive patients with gout or asymptomatic hyperuricemia: a pooled analysis of individual participant data in phase II and III trials

Clinical and experimental hypertension (1993), 2021-11, Vol.43 (8), p.730-741

2021

Volltextzugriff (PDF)

A non-inferiority study of the novel selective urate reabsorption inhibitor dotinurad versus febuxostat in hyperuricemic patients with or without gout

Clinical and experimental nephrology, 2020-03, Vol.24 (Suppl 1), p.71-79

2020

Volltextzugriff (PDF)

Dotinurad versus benzbromarone in Japanese hyperuricemic patient with or without gout: a randomized, double-blind, parallel-group, phase 3 study

Clinical and experimental nephrology, 2020-03, Vol.24 (Suppl 1), p.62-70

2020

Volltextzugriff (PDF)

Low Glomerular Density with Glomerulomegaly in Obesity-Related Glomerulopathy

Clinical journal of the American Society of Nephrology, 2012-05, Vol.7 (5), p.735-741

2012

Volltextzugriff (PDF)

Effects of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without gout

Clinical and experimental nephrology, 2014-12, Vol.18 (6), p.876-884

2014

Volltextzugriff (PDF)

Open-label study of long-term administration of dotinurad in Japanese hyperuricemic patients with or without gout

Clinical and experimental nephrology, 2020-03, Vol.24 (Suppl 1), p.80-91

2020

Volltextzugriff (PDF)

Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: randomized, multicenter, double-blind, placebo-controlled, parallel-group, confirmatory phase 2 study

Clinical and experimental nephrology, 2020-03, Vol.24 (Suppl 1), p.53-61

2020

Volltextzugriff (PDF)

Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: an exploratory, randomized, multicenter, double-blind, placebo-controlled, parallel-group early phase 2 study

Clinical and experimental nephrology, 2020-03, Vol.24 (Suppl 1), p.44-52

2020

Volltextzugriff (PDF)

Effects of mild and moderate renal dysfunction on pharmacokinetics, pharmacodynamics, and safety of dotinurad: a novel selective urate reabsorption inhibitor

Clinical and experimental nephrology, 2020-03, Vol.24 (Suppl 1), p.17-24

2020

Volltextzugriff (PDF)

Uric acid-lowering and renoprotective effects of topiroxostat, a selective xanthine oxidoreductase inhibitor, in patients with diabetic nephropathy and hyperuricemia: a randomized, double-blind, placebo-controlled, parallel-group study (UPWARD study)

Clinical and experimental nephrology, 2018-08, Vol.22 (4), p.860-870

2018

Volltextzugriff (PDF)

A clinical pharmacology study of the novel, selective urate reabsorption inhibitor dotinurad in outpatients

Clinical and experimental nephrology, 2020-03, Vol.24 (Suppl 1), p.103-111

2020

Volltextzugriff (PDF)

Common dysfunctional variants in ABCG2 are a major cause of early-onset gout

Scientific reports, 2013-06, Vol.3 (1), p.2014-2014, Article 2014

2013

Volltextzugriff (PDF)

Serum uric acid and the incidence of CKD and hypertension

Clinical and experimental nephrology, 2015-12, Vol.19 (6), p.1127-1134

2015

Volltextzugriff (PDF)

Clinical feasibility of transfer to combined therapy with peritoneal dialysis and hemodialysis for patients on peritoneal dialysis: A prospective multicenter study in Japan

Therapeutic apheresis and dialysis, 2022-12, Vol.26 (6), p.1226-1234

2022

Volltextzugriff (PDF)

Clinical features and long-term renal outcomes of Japanese patients with obesity-related glomerulopathy

Clinical and experimental nephrology, 2013-06, Vol.17 (3), p.379-385

2013

Volltextzugriff (PDF)

Common dysfunctional variants of ABCG2 have stronger impact on hyperuricemia progression than typical environmental risk factors

Scientific reports, 2014-06, Vol.4 (1), p.5227, Article 5227

2014

Volltextzugriff (PDF)

Gender interaction of uric acid in the development of hypertension

Clinical and experimental hypertension (1993), 2018-01, Vol.40 (5), p.446-451

2018

Volltextzugriff (PDF)

Keap1 inhibition attenuates glomerulosclerosis

Nephrology, dialysis, transplantation, 2014-04, Vol.29 (4), p.783-791

2014

Volltextzugriff (PDF)

PGD2-CRTH2 Pathway Promotes Tubulointerstitial Fibrosis

Journal of the American Society of Nephrology, 2012-11, Vol.23 (11), p.1797-1809

2012

Volltextzugriff (PDF)

Laparoscopic approach for the evaluation of peritoneal injury

Kidney international, 2012-07, Vol.82 (2), p.244-245

2012

Volltextzugriff (PDF)

Low glomerular density is a risk factor for progression in idiopathic membranous nephropathy

Nephrology, dialysis, transplantation, 2011-11, Vol.26 (11), p.3555-3560

2011

Volltextzugriff (PDF)

A repeated oral administration study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with impaired renal function in Japan: pharmacokinetic and pharmacodynamic study

Journal of clinical rheumatology, 2011-06, Vol.17 (4 Suppl 2), p.S27

2011

Volltextzugriff (PDF)

1 – 25 von 565

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(336)
Mit Volltextzugriff
(511)

Publikationsform

Sprache

Englisch
(405)
Japanisch
(274)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Safety, efficacy and renal effect of febuxostat in patients with moderate-to-severe kidney dysfunction

Decreased extra-renal urate excretion is a common cause of hyperuricemia

Comparative study of a novel selective urate reabsorption inhibitor “dotinurad” among patient groups with different stages of renal dysfunction

Uric acid-lowering effect of dotinurad, a novel selective urate reabsorption inhibitor, in hypertensive patients with gout or asymptomatic hyperuricemia: a pooled analysis of individual participant data in phase II and III trials

A non-inferiority study of the novel selective urate reabsorption inhibitor dotinurad versus febuxostat in hyperuricemic patients with or without gout

Dotinurad versus benzbromarone in Japanese hyperuricemic patient with or without gout: a randomized, double-blind, parallel-group, phase 3 study

Low Glomerular Density with Glomerulomegaly in Obesity-Related Glomerulopathy

Effects of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without gout

Open-label study of long-term administration of dotinurad in Japanese hyperuricemic patients with or without gout

Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: randomized, multicenter, double-blind, placebo-controlled, parallel-group, confirmatory phase 2 study

Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: an exploratory, randomized, multicenter, double-blind, placebo-controlled, parallel-group early phase 2 study

Effects of mild and moderate renal dysfunction on pharmacokinetics, pharmacodynamics, and safety of dotinurad: a novel selective urate reabsorption inhibitor

Uric acid-lowering and renoprotective effects of topiroxostat, a selective xanthine oxidoreductase inhibitor, in patients with diabetic nephropathy and hyperuricemia: a randomized, double-blind, placebo-controlled, parallel-group study (UPWARD study)

A clinical pharmacology study of the novel, selective urate reabsorption inhibitor dotinurad in outpatients

Common dysfunctional variants in ABCG2 are a major cause of early-onset gout

Serum uric acid and the incidence of CKD and hypertension

Clinical feasibility of transfer to combined therapy with peritoneal dialysis and hemodialysis for patients on peritoneal dialysis: A prospective multicenter study in Japan

Clinical features and long-term renal outcomes of Japanese patients with obesity-related glomerulopathy

Common dysfunctional variants of ABCG2 have stronger impact on hyperuricemia progression than typical environmental risk factors

Gender interaction of uric acid in the development of hypertension

Keap1 inhibition attenuates glomerulosclerosis

PGD2-CRTH2 Pathway Promotes Tubulointerstitial Fibrosis

Laparoscopic approach for the evaluation of peritoneal injury

Low glomerular density is a risk factor for progression in idiopathic membranous nephropathy

A repeated oral administration study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with impaired renal function in Japan: pharmacokinetic and pharmacodynamic study

Suchergebnisse filtern